1
|
Chen F, Ma S, Wang R, Chen D, Wen C, Wang X, Hu T, Shen X. Advanced UPLC-MS/MS Method for the Quantification of SIPI6398 in Rat Plasma and Its Pharmacokinetic Characterization. JOURNAL OF ANALYTICAL METHODS IN CHEMISTRY 2024; 2024:9811466. [PMID: 38742189 PMCID: PMC11090672 DOI: 10.1155/2024/9811466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 04/10/2024] [Accepted: 04/22/2024] [Indexed: 05/16/2024]
Abstract
SIPI6398 is a novel anti-schizophrenia agent with a new mechanism of action and demonstrates better target selectivity and safety compared to its competitors. However, few in vivo studies on the pharmacokinetics and bioavailability of SIPI6398 have been performed. A rapid and simple ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) approach was developed for accurate quantification of SIPI6398 in rat plasma. A simple protein precipitation of acetonitrile-methanol (9 : 1, v/v) was used to treat plasma. Chromatography was performed on a UPLC HSS T3 column (50 mm × 2.1 mm, 1.8 μm) at a flow rate of 0.4 ml/min. The mobile phase consisted of acetonitrile-water (with 0.1% formic acid) and gradient elution was used, and the elution time was 4 minutes. Quantitative analysis was performed using electrospray ionization (ESI) in positive ion detection mode with multiple reaction monitoring (MRM) mode. To evaluate the pharmacokinetics and bioavailability, SIPI6398 was administered to rats in two different ways: oral (4 mg/kg) and intravenous (2 mg/kg) administration. The calibration curve for the UPLC-MS/MS approach shows excellent linearity in the range of 1-2000 ng/mL with an r value above 0.99. The precision, accuracy, recovery, matrix effect, and stability results all meet the criteria established for biological analytical methods. The UPLC-MS/MS method was successfully applied it to pharmacokinetics study of SIPI6398. The bioavailability of SIPI6398 was calculated to be 13.2%. These studies have the potential to contribute towards a more comprehensive comprehension of the pharmacokinetics and bioavailability of SIPI6398.
Collapse
Affiliation(s)
- Fan Chen
- Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
| | - Shunjun Ma
- Laboratory Animal Centre, Wenzhou Medical University, Wenzhou, China
| | - Runrun Wang
- Laboratory Animal Centre, Wenzhou Medical University, Wenzhou, China
| | - Dizhong Chen
- Laboratory Animal Centre, Wenzhou Medical University, Wenzhou, China
| | - Congcong Wen
- Laboratory Animal Centre, Wenzhou Medical University, Wenzhou, China
| | - Xianqin Wang
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
| | - Tao Hu
- Department of Thoracic Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China
| | - Xiuwei Shen
- Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
| |
Collapse
|
2
|
Yu K, Zhou H, Chen Z, Lei Y, Wu J, Yuan Q, He J. Mechanism of cognitive impairment and white matter damage in the MK-801 mice model of schizophrenia treated with quetiapine. Behav Brain Res 2024; 461:114838. [PMID: 38157989 DOI: 10.1016/j.bbr.2023.114838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 12/11/2023] [Accepted: 12/23/2023] [Indexed: 01/03/2024]
Abstract
Schizophrenia has been linked to cognitive impairment and white matter damage in a growing number of studies this year. In this study, we used the MK-801-induced schizophrenia-like mice model to investigate the effects of quetiapine on behavioral changes and myelin loss in the model mice. The subjects selected for this study were C57B6/J male mice, MK-801 (1 mg/kg/d intraperitoneal injection) modeling for 1 week and quetiapine (10 mg/kg/d intraperitoneal injection) treatment for 2 weeks. Behavioral tests were then performed using the three-chamber paradigm test and the Y maze test. Moreover, western blot, immunohistochemistry, and immunofluorescence were conducted to investigate the changes in oligodendrocyte spectrum markers. In addition, we performed some mechanism-related proteins by western blot. Quetiapine ameliorated cognitive impairment and cerebral white matter damage in MK-801 model mice, and the mechanism may be related to the PI3K/AKT pathways. The present study suggests that quetiapine has a possible mechanism for treating cognitive impairment and white matter damage caused by schizophrenia.
Collapse
Affiliation(s)
- Kai Yu
- School of Mental Health and the Affiliated Kangning Hospital, Wenzhou Key Laboratory for Basic and Translational Research in Mental Health, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Han Zhou
- School of Mental Health and the Affiliated Kangning Hospital, Wenzhou Key Laboratory for Basic and Translational Research in Mental Health, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Zhuo Chen
- School of Mental Health and the Affiliated Kangning Hospital, Wenzhou Key Laboratory for Basic and Translational Research in Mental Health, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Yuying Lei
- School of Mental Health and the Affiliated Kangning Hospital, Wenzhou Key Laboratory for Basic and Translational Research in Mental Health, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Junnan Wu
- School of Mental Health and the Affiliated Kangning Hospital, Wenzhou Key Laboratory for Basic and Translational Research in Mental Health, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Qianfa Yuan
- Xiamen Xian Yue Hospital, Xiamen, Fujian, China
| | - Jue He
- School of Mental Health and the Affiliated Kangning Hospital, Wenzhou Key Laboratory for Basic and Translational Research in Mental Health, Zhejiang Provincial Clinical Research Center for Mental Disorders, Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, Zhejiang, China; Institute of Neurological Disease, First Affiliated Hospital, Henan University, Kaifeng, Henan, China.
| |
Collapse
|